TMDIF vs. LUCD, OBIO, LUNG, ZJYL, MGRM, ICAD, FONR, NTRB, MBOT, and CTSO
Should you be buying Titan Medical stock or one of its competitors? The main competitors of Titan Medical include Lucid Diagnostics (LUCD), Orchestra BioMed (OBIO), Pulmonx (LUNG), Jin Medical International (ZJYL), Monogram Orthopaedics (MGRM), icad (ICAD), Fonar (FONR), Nutriband (NTRB), Microbot Medical (MBOT), and Cytosorbents (CTSO). These companies are all part of the "medical equipment" industry.
Titan Medical vs. Its Competitors
Lucid Diagnostics (NASDAQ:LUCD) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.
Lucid Diagnostics has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Titan Medical has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.
Titan Medical has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -1,699.86%. Lucid Diagnostics' return on equity of 0.00% beat Titan Medical's return on equity.
In the previous week, Lucid Diagnostics' average media sentiment score of 0.00 equaled Titan Medical'saverage media sentiment score.
74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 0.0% of Titan Medical shares are owned by institutional investors. 6.8% of Lucid Diagnostics shares are owned by insiders. Comparatively, 0.0% of Titan Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Lucid Diagnostics presently has a consensus price target of $3.55, suggesting a potential upside of 226.89%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Lucid Diagnostics is more favorable than Titan Medical.
Titan Medical has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Lucid Diagnostics beats Titan Medical on 8 of the 15 factors compared between the two stocks.
Get Titan Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMDIF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TMDIF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TMDIF vs. The Competition
Titan Medical Competitors List
Related Companies and Tools
This page (NASDAQ:TMDIF) was last updated on 7/5/2025 by MarketBeat.com Staff
